Hloov Citrus Pectin (MCP), ib tug hwm dej-soluble, nondigestible polysaccharide derived los ntawm citrus peels, yog tawm los ntawm cov neeg tsis muaj tshuaj tiv thaiv kev tawm tsammob kha xaw, tshwj xeeb rau kev tsom mus rau cov txheej txheem ntawm metastasis. Nws cov qauv siab tshaj plaws ua rau muaj kev cuam tshuam ntawm Galectin-3, carbohydrate protein (lectin) thuam kev ua kom muaj kev mob cancer.
Zhejiang kub kropn biotechnology Co., Ltd. yog National High Enterprise Kev Tshawb Fawb Kev Tshawb Fawb, ntau lawm, thiab kev muag khoom. Hauv kev koom tes nrog cov tuam txhab kev kawm xws li Zhejian University, Tianjin University, thiab Xinxian University, thiab Xinxiang Health cov khoom noj kev noj qab haus huv Nws cov khoom yog xa tawm rau ntau lub teb chaws thiab cheeb tsam cheeb tsam thoob ntiaj teb.
Hloov Citrus pectin (MCP) raug lees paub tias yog cov khoom noj muaj kev nyab xeeb ntawm cov khoom noj ntxiv (ADI)
Kub Kropn ua haujlwm 100,000-qib GMP-cov ntaub ntawv muaj ntawv pov thawj tsim khoom lag luam txiv qaub li cov khoom siv raw thiab ua haujlwm siab ua kom tiav cov khoom siv hydrolysis kom rho tawm qib siab mcp. Txhua kauj ruam ntawm cov txheej txheem - los ntawm raw cov khoom siv rau kev tsim khoom rau kev tsim-yog nruj me ntsis tswj. Lub tuam txhab ua cov khoom xyaw rau cov khoom xyaw ntuj thiab cov txheej txheem kev ntxuav kom huv ntau yam kom ntseeg tau tias cov khoom muaj kev nyab xeeb thiab kev nyab xeeb zoo dua.
Galectin-3 plays lub luag haujlwm tseem ceeb hauv cov qog nqaij hlav Metastasis los ntawm kev sib tw ntawm cov hlab ntsha, thiab kev tsim tawm cov qog ntshav ntawm cov chaw nyob deb ntawm cov tub rog hauv lub neej. Qhov tseem ceeb, nws tseem txhawb kom Angiogenesis, kev tsim ntawm cov ntshav tshiab tseem ceeb rau cov qog nqaij hlav loj hlob thiab kis tau. Kev tshawb fawb qhia pom tias MCP los ntawm kub kropn ua raws li kev loj-authinity ligand rau Galectin-3. Los ntawm kev khi rau nws cov carbohydrate conceptition demain, Kub Kropn sib txuam Qhov no blockade cuam tshuam cov tseem ceeb Galectin-3-deliated cov haujlwm.
Preclinical kev tshawb fawb muab pov thawj ua pov thawj rau qhov cuam tshuam ntawmMCP thiab CancerMetastasis. Nyob rau hauv liab qab nas cov qauv:
Kev txhaj tshuaj lossis tshuaj tiv thaiv kab mob hlwb (MDA-MB-435) rau hauv cov phamatary rog pad ua rau ib qho tseem ceeb70.2% txo qis hauv thawj cov qogTom qab 7 lub lis piam ntawm qhov ncauj MCP los ntawm kub Kropn Kev tswj hwm (1% hauv cov dej haus) piv rau kev tswj hwm. Qhov no tau nrog kev tawm tsam66% txo cov qog-cuam tshuam cov hlab ntshav(Angiogenisesis Inhibition) thiab aKev tiv thaiv tiav ntawm Spontaneous Lung MetaSasis(0/8 MCP-Fed Mice vs . 6} / 9 Tswj Mice).
Kev phais mob ntawm cov metastatic tib neeg txoj hnyuv carcinoma hlwb (LSLIM6) rau hauv Cecum pomho txo cov qog thawj cov qog qhov hnyav thiab cov qog hauv plabhauvMCP-Fed MiceCov. Ntau dua, Metastasis rau cov qog ntshav poob los ntawm100% (9/9) hauv kev tswj hwm 25% (2/8)nrogMcp, thiab nplooj siab metastasis plummeted los ntawm60% (6/10) rau 0% (0/9).
Kev tshawb fawb ua ntej (siv prostate cancer thiab melanoma qauv) dlrig nrog cov kev tshawb pom no, qhia44% -70% txo qis hauv Lung MetastasesThaum kho nrog cov qauv zoo MCP cov qauv zoo liKub Kropn.
Cov hauv kev tshawb fawb hauv cov ntawv tshawb fawb elucating lub cellular mechanisms tom qab cov teebmeem no. MCP los ntawm kub Kropn:
Inhibits Galectin-3 khi:Dose-ntseeg tau thaiv cov kev khi ntawm Galectin-3 rau tib neeg Umbilical Vein Opothelial hlwb (Huvecs) -up rau95.8% Inhibition ntawm 0.25% MCP.
Inhibits Angiogenesis:Tiv thaiv Huvec Capillary raj tsim ntawm malrigel hauv ib qho koob tshuaj--nqi, ncaj qha txuasKub Kropn McPrau anti-angiogenic cuam tshuam.
Inhibits chemotaxis:Ho txo qis (68% ntawm 0.005%) thiabTag nrho cov blocks (ntawm 0.1%)Hutec tsiv teb tsaws mus rau Galectin-3. Nws tseem qhia qhov cuam tshuam tiv thaiv kev tsiv teb tsaws chaw uas tau tsim los ntawm lwm yam zoo li BFGF.
Txwv tsis pub cov qog-endothelial adhesion:Koob tshuaj-nyob ze rau cov nplaum ntawm Galectin-3-qhia txog cov kab mob cancer mis (MDA-MB-435) rau HUVECS (txog li 83.4% inhibition nyob rau 0.25% MCP), ib qib tseem ceeb hauv Metastasis.
Clinically, tusKev sib raug zoo ntawm MCP thiab CancerKev vam meej yog txhawb los ntawm kev txhim kho biomarker. Nyob rau hauv theem II sim nrog cov neeg mob nrog cov qog ua tau zoo,21% tiav cov kab mob sib tsoonrogMCP SuppulitionationCov. Rau prostatemob kha xawCov neeg mob,MCP tseem txuas ntxiv psa doubling sijhawm (PSadt) hauv 70% ntawm cov neeg muaj mobNrog biochemical kev rov muaj dua, qhia tau qeeb qog kev loj hlob. Cov peev xwm no kom qeeb zuj zus thiab kev tiv thaiv metastasis tshwj xeeb yog qhov tshwj xeeb rau theem IV cov neeg mob.
Ib qho loj ntawmMcpLos ntawm Kub Kropnyog nwsdej siab kev nyab xeeb thiab cov tshuaj lom tsawg, Tso cai rau kev tswj hwm qhov ncauj ntev hauv txuas nrog kev kho kom zoo ib yam li kev kho mob thiab hluav taws xob. Kev Tshawb Fawb QhiaMcptej zaum kuj yuav siv cov khoom noj nrog cov kev kho no. Kev tshawb nrhiav ntawmMCP thiab Cancer immunotherapiesyog ib qho kev cog lus yav tom ntej.
Hauv kev xaus,Mcpsawv cev atshiab, tsis muaj tshuaj lom kev noj haus zooKev sib tw Galectin-3 txhawm rau tawm tsam kev mob siab rau metastas thiab Angiogenesis. Thaum lub sij hawm cov kev sim siab ntau dua los tsim kom haum nws txoj haujlwm kho kom zoo thiab cov ntaub ntawv ua haujlwm uas twb muaj lawm.McpLos ntawm Kub Kropnmuajcomprementary mus rau kev cuam tshuam lub metastatic cascade, muaj peev xwm txhim kho cov txiaj ntsig thiab lub neej zoo rau cov neeg mob qog nqaij hlav, tshwj xeeb yog cov uas muaj tus kab mob siab heev.